Figure 8.

Antiviral potency of AVG-233. A, virus yield reduction of RSV A2-L19F and two RSV clinical strains by AVG-233. Infected cells were incubated in the presence of compound, and progeny virus titers were determined 48 h after infection. Active concentrations were determined through four-parameter variable slope regression modeling. LoD, level of detection. B, antiviral activity of first- and second-generation lead analogs AVG-158 and AVG-233, respectively, in undifferentiated primary HBTECs. Four-parameter variable slope regression models and active concentrations are shown. Symbols in A and B represent individual biological repeats (n = 3 each or greater); error bars, S.D.